ABL Bio Presents Efficacy of Bispecific Antibody Immuno-Oncology Drug at American Association for Cancer Research

[Asia Economy Reporter Hyungsoo Park] ABL Bio disclosed an abstract at the American Association for Cancer Research (AACR) on the 15th, Eastern Time in the United States.

At the AACR abstract presentation, ABL Bio participated as a co-research company in a total of four poster presentations: two pipelines jointly researched with I-Mab, one pipeline jointly researched with Yuhan Corporation, and a project conducted together with Pohang University of Science and Technology (POSTECH).

The bispecific antibody immuno-oncology drug ABL503 attracted attention among bio industry insiders for its ability to suppress liver toxicity. It also demonstrated improved anticancer effects compared to single antibodies by proliferating and activating T immune cells.

ABL Bio is developing the bispecific antibody immuno-oncology drugs ABL503 and ABL501 with the goal of completing preclinical toxicity tests and initiating clinical trials by the end of this year, and ABL111 by the first half of next year.

At the domestic bio event "Bio Korea 2020," ABL Bio announced ABL202 (LCB71), a candidate targeted therapy for triple-negative breast cancer and hematologic cancers targeting ROR1. ABL202 is an antibody-drug conjugate (ADC) pipeline that eliminates cancer cells expressing ROR1. ADC is a technology that binds drugs to antibodies to target cancer cells, and it is praised for being more effective and having fewer side effects compared to conventional anticancer treatments. This substance also showed efficacy in animal models by effectively suppressing or killing tumor growth.

Based on the current toxicity test results, ABL Bio is jointly developing ABL202 as a ROR1-targeted anticancer drug with LegoChem Biosciences.

This content was produced with the assistance of AI translation services.